Last update at 2025-07-04T16:44:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
18 Best 52-Week Low Stocks To Buy Now
Sat 27 Jan 24, 10:29 AMAre Medical Stocks Lagging Adicet Bio (ACET) This Year?
Tue 09 Jan 24, 09:49 PM12 Most Profitable Pot Stocks Now
Wed 27 Dec 23, 11:37 PMAurora Cannabis Inc. (TSE:ACB) Is Expected To Breakeven In The Near Future
Tue 12 Dec 23, 11:06 AMCould Aurora Cannabis Be a Screaming Buy Right Now?
Sun 10 Dec 23, 01:08 PMIs Aurora Cannabis Stock a Buy Now?
Wed 06 Dec 23, 01:42 PMDown 99.5%, Is Now the Time to Buy Aurora Cannabis?
Wed 06 Dec 23, 10:52 AMWeekly Roundup on the Cannabis Sector & Psychedelic Sector
Mon 08 Aug 22, 11:00 AMBreakdown | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
Income before tax | -59.59900M | -221.53200M | -264.54867M | -1720.12000M | -1720.12000M |
Minority interest | - | - | 2.06M | 0.35M | 0.35M |
Net income | -69.32600M | -198.99700M | -263.78601M | -1717.97900M | -1717.62400M |
Selling general administrative | 104.94M | 133.40M | 68.22M | 126.97M | 126.97M |
Selling and marketing expenses | 51.94M | - | 51.97M | 62.02M | 62.02M |
Gross profit | 131.46M | -33.35400M | -60.44518M | 21.23M | 21.23M |
Reconciled depreciation | 33.07M | - | 65.23M | 93.66M | 93.66M |
Ebit | -12.59700M | - | -245.49672M | -219.37500M | -236.74900M |
Ebitda | 20.47M | - | -203.31683M | -143.08900M | -143.08900M |
Depreciation and amortization | 33.07M | - | 42.18M | 76.29M | 93.66M |
Non operating income net other | - | - | - | - | - |
Operating income | -46.45300M | -220.67800M | -245.49672M | -219.37500M | -231.44900M |
Other operating expenses | 297.36M | - | 477.08M | 440.71M | 440.71M |
Interest expense | 14.19M | - | 39.46M | 71.81M | 71.81M |
Tax provision | -0.55400M | -15.23700M | -15.23700M | -2.14100M | -2.14100M |
Interest income | 12.81M | 2.53M | 2.53M | 4.51M | 4.51M |
Net interest income | -1.37300M | - | -51.52500M | -67.30600M | -67.30600M |
Extraordinary items | - | - | - | 0.00000M | 0.00000M |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -0.55400M | - | -20.24528M | -2.14100M | -2.14100M |
Total revenue | 270.28M | 174.97M | 231.58M | 221.34M | 221.34M |
Total operating expenses | 158.54M | - | 185.05M | 240.60M | 240.60M |
Cost of revenue | 138.82M | 208.32M | 292.03M | 200.11M | 200.11M |
Total other income expense net | -31.14700M | - | -19.05195M | -1500.74500M | -1433.43900M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -59.04500M | - | -1750.02200M | -1717.97900M | -1717.97900M |
Net income applicable to common shares | - | -198.99700M | -198.99700M | -1717.62400M | -1717.62400M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2025-03-31 | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2025-03-31 | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 |
Total assets | 852.67M | 838.67M | 926.32M | 926.32M | 1084.36M |
Intangible assets | 45.16M | 40.85M | 59.68M | 61.40M | 70.70M |
Earning assets | - | - | - | - | - |
Other current assets | 10.66M | 9.40M | 66.54M | 8.92M | 119.01M |
Total liab | 244.07M | 236.80M | 440.25M | 404.62M | 422.00M |
Total stockholder equity | 567.17M | 559.77M | 486.08M | 490.64M | 661.84M |
Deferred long term liab | - | - | - | - | - |
Other current liab | - | 45.39M | - | 66.50M | 94.52M |
Common stock | - | 6971.42M | 6841.23M | 6841.23M | 6754.63M |
Capital stock | 6991.15M | 6971.42M | - | - | 6754.63M |
Retained earnings | -6367.74500M | -6367.93600M | -6056.41200M | -6292.26500M | -6038.27500M |
Other liab | - | - | - | - | 40.29M |
Good will | 43.87M | 43.18M | 18.71M | 18.71M | 0.00000M |
Other assets | - | - | 38.53M | 38.53M | 33.87M |
Cash | 137.92M | 113.44M | - | 300.84M | 437.81M |
Cash and equivalents | - | - | 234.94M | 234.94M | 437.81M |
Total current liabilities | 110.86M | 124.62M | 242.31M | 237.74M | 145.23M |
Current deferred revenue | - | 1.69M | - | 1.74M | 3.85M |
Net debt | - | -8.64800M | - | -73.32000M | -168.31600M |
Short term debt | - | 57.22M | 0.00000M | 147.56M | 33.00M |
Short long term debt | 21.51M | 52.36M | - | - | 26.85M |
Short long term debt total | - | 104.79M | - | 227.52M | 269.49M |
Other stockholder equity | - | - | -298.74600M | -0.00000M | -54.50800M |
Property plant equipment | - | - | 322.97M | 322.97M | 230.30M |
Total current assets | 478.33M | 426.61M | 479.93M | 479.93M | 745.12M |
Long term investments | - | - | - | - | 1.21M |
Net tangible assets | - | - | - | - | 587.99M |
Short term investments | 0.55M | 4.04M | 0.00000M | 0.00000M | 1.33M |
Net receivables | 35.02M | 45.41M | 35.02M | 41.34M | 47.05M |
Long term debt | 40.19M | 4.90M | 36.16M | 36.16M | 199.65M |
Inventory | 239.09M | 186.38M | 128.82M | 128.82M | 139.93M |
Accounts payable | 27.62M | 20.32M | - | 21.94M | 13.86M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | -43.70700M | - | -58.32500M | -54.50800M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 7.72M | 12.03M | - | 14.06M | 33.87M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 374.34M | 412.07M | - | 446.39M | 339.24M |
Capital lease obligations | 42.88M | 47.53M | - | - | 42.99M |
Long term debt total | - | - | 79.97M | 79.97M | 236.49M |
Breakdown | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
Investments | -5.48700M | - | -54.67400M | -36.60000M | -36.60000M |
Change to liabilities | - | - | - | 3.31M | 3.31M |
Total cashflows from investing activities | - | -27.29100M | -27.29100M | -36.60000M | -36.60000M |
Net borrowings | - | - | - | -170.83100M | -170.83100M |
Total cash from financing activities | -47.92300M | -71.40600M | -56.47800M | 147.78M | 147.78M |
Change to operating activities | - | - | - | 6.47M | 6.47M |
Net income | -59.04500M | -206.29500M | -234.57275M | -1717.97900M | -1717.97900M |
Change in cash | -121.50300M | -202.86500M | -140.00900M | 16.35M | 16.35M |
Begin period cash flow | 234.94M | 437.81M | 440.85M | 421.46M | 421.46M |
End period cash flow | 113.44M | - | 300.84M | 437.81M | 437.81M |
Total cash from operating activities | -68.50800M | -115.82100M | -115.80500M | -109.83800M | -109.83800M |
Issuance of capital stock | 37.93M | - | 417.75M | 350.19M | 350.19M |
Depreciation | 33.07M | 31.99M | 42.18M | 93.66M | 93.66M |
Other cashflows from investing activities | - | -15.15900M | -15.15900M | -0.18500M | -0.18500M |
Dividends paid | - | - | - | - | - |
Change to inventory | 3.62M | - | 49.51M | 21.07M | 21.07M |
Change to account receivables | -4.33300M | - | 2.97M | 18.76M | 18.76M |
Sale purchase of stock | - | 73.19M | 73.19M | 350.19M | 350.19M |
Other cashflows from financing activities | -0.08900M | -14.92800M | -0.12300M | -31.57800M | -31.57800M |
Change to netincome | - | - | - | 1464.18M | 1464.18M |
Capital expenditures | 16.96M | 12.13M | 9.33M | 32.21M | 32.21M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -15.62700M | -25.11600M | -24.83600M | 49.95M | 49.95M |
Stock based compensation | 12.72M | - | 16.89M | 13.76M | 13.76M |
Other non cash items | -70.84100M | - | 159.74M | 1452.97M | 1452.97M |
Free cash flow | -85.46400M | - | -125.13200M | -142.05100M | -142.05100M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
ACB Aurora Cannabis Inc |
0.02 0.32% | 6.22 | 18.23 | 90.91 | 0.90 | 0.54 | 0.80 | 5.33 |
BHC Bausch Health Companies Inc |
-0.02 0.21% | 9.42 | - | 1.69 | 0.32 | 18.74 | 2.33 | 8.07 |
CRON Cronos Group Inc |
0.01 0.36% | 2.77 | 13.68 | - | 8.04 | 0.67 | 0.02 | -1.9458 |
CURA Curaleaf Holdings Inc. |
0.01 0.89% | 1.14 | - | 138.89 | 0.62 | 0.72 | 1.00 | 5.90 |
GUD Knight Therapeutics Inc. |
0.01 0.25% | 6.04 | 60.30 | 80.65 | 1.61 | 0.76 | 1.27 | 6.84 |
Aurora Cannabis Inc., together with its subsidiaries, engages in production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; sale of medical and consumer use cannabis products; and the propagation of vegetables and floral plants. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
90B Street SW, Edmonton, AB, Canada, T6X 1V8
Name | Title | Year Born |
---|---|---|
Mr. Miguel Martin | CEO & Director | 1972 |
Mr. Glen Ibbott | Chief Financial Officer | NA |
Mr. Alex Miller | Exec. VP of Operations & Supply Chain | NA |
Ms. Lori Schick | Exec. VP of HR | NA |
Mr. Andre Jerome | Exec. VP of Global Bus. Devel. | NA |
Ananth Krishnan | VP of Capital Markets & Investor Relations | NA |
Mr. Nathalie Clark | Exec. VP, Gen. Counsel & Corp. Sec. | NA |
Michelle Lefler | VP of Communications & PR | NA |
Mr. Carey Squires | Exec. VP of Corp. Devel. & Strategy | NA |
Mr. John Barnet | Chief Cultivator | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.